title: Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor, decreases serum uric acid levels in type 2 diabetic patients partly by suppressing xanthine oxidase activity.
authors: Department of Pathophysiology and Therapeutics of Diabetic Vascular Complications, Kurume University School of Medicine, Kurume, Japan. Electronic address: shoichi@med.kurume-u.ac.jp.
authors: Sho-ichi
authors: S
authors: Yamagishi
authors: Department of Pathophysiology and Therapeutics of Diabetic Vascular Complications, Kurume University School of Medicine, Kurume, Japan.
authors: Yuji
authors: Y
authors: Ishibashi
authors: Department of Pathophysiology and Therapeutics of Diabetic Vascular Complications, Kurume University School of Medicine, Kurume, Japan.
authors: Ayako
authors: A
authors: Ojima
authors: Seiwa Clinic, Tokyo, Japan.
authors: Tatsushi
authors: T
authors: Sugiura
authors: Department of Pathophysiology and Therapeutics of Diabetic Vascular Complications, Kurume University School of Medicine, Kurume, Japan.
authors: Takanori
authors: T
authors: Matsui
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000188:drug therapy*; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004791:Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology / Q000627:therapeutic use; D000069476:Linagliptin; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011687:Purines / Q000494:pharmacology / Q000627:therapeutic use*; D011799:Quinazolines / Q000494:pharmacology / Q000627:therapeutic use*; D014527:Uric Acid / Q000037:antagonists & inhibitors / Q000097:blood*; D014969:Xanthine Oxidase / Q000037:antagonists & inhibitors* / Q000378:metabolism
chemical_list: D054873:Dipeptidyl-Peptidase IV Inhibitors; D004791:Enzyme Inhibitors; D007004:Hypoglycemic Agents; D011687:Purines; D011799:Quinazolines; D014527:Uric Acid; D000069476:Linagliptin; D014969:Xanthine Oxidase
keywords: Atherosclerosis; DPP-4 inhibitor; Inflammation; Linagliptin; Oxidative stress; Type 2 diabetes; Uric acid; Vascular complications; Vascular damage; Xanthine oxidase